Why is Alembic Pharma falling/rising?

As of 14-Jul, Alembic Pharmaceuticals Ltd. is experiencing a rise in its stock price, currently at 1,030.30, reflecting an increase of 55.3 points or 5.67%. The stock has shown a trend reversal, gaining after four consecutive days of decline, and has outperformed its sector by 4.77%. It reached an intraday high of Rs 1039, and is trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages. Despite a year-to-date decline of 2.72%, the stock has generated a return of 4.64% over the past year, although profits have decreased by 7%. The company maintains a strong ability to service debt, indicated by a low Debt to EBITDA ratio of 0.67 times, and has high institutional holdings at 20.37%, which may contribute to investor confidence.
Broader Market Context: In the short term, Alembic Pharmaceuticals has outperformed the benchmark Sensex, which has declined by 1.42% over the past week while Alembic's stock has increased by 3.03%. This contrast highlights the stock's relative strength in a challenging market environment. However, it is important to note that the stock's long-term growth prospects are hindered by a negative annual operating profit growth rate of -7.30% over the last five years, and recent negative results, including a significant drop in PAT. These factors suggest that while the stock is currently rising, there are underlying challenges that could impact its future performance.